News

Scientists have developed a way to use engineered specialized stem cells to regenerate healthy airway tissues, offering a potential avenue for treating chronic lung diseases like pulmonary fibrosis (PF). In a pair of proof-of-concept preclinical studies published in Cell Stem Cell, scientists described how they engineered lung stem…

Supporters are gearing up to mark Pulmonary Fibrosis Awareness Month, set aside every September, to call attention to the rare lung disease that affects more than 250,000 individuals in the U.S. and 400,000 in Europe. For its part, the Pulmonary Fibrosis Foundation (PFF), with its campaign theme “Embrace Your…

The U.S. Food and Drug Administration (FDA) has approved a new generic version of Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF), according to an announcement by Lupin, the global pharmaceutical company that will market the medication. As with the brand name medicine, Lupin‘s generic will be available…

Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s now being tested in clinical trials, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies with the potential to substantially improve care for people with rare diseases,…

Many people with idiopathic pulmonary fibrosis (IPF) in the U.S. are not diagnosed early enough or given treatments helping to low its progression in a timely fashion, a large data study found. Although more is known about risk factors for IPF, delays are evident in diagnosis and the…

GB0139, an investigational inhaled treatment for idiopathic pulmonary fibrosis (IPF), failed to slow lung decline in IPF patients compared with a placebo, according to top-line data from the Phase 2b GALACTIC-1 trial. GB0139’s developer Galecto will discontinue the treatment. “We are very disappointed that the GALACTIC-1 results…

Trevi Therapeutics is planning to launch two new clinical trials this fall to test Haduvio (nalbuphine extended-release tablets) for chronic cough in people with idiopathic pulmonary fibrosis (IPF). One of the trials will be a Phase 2b study to identify the best dose of the medication for…

Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, it intends to recruit about 270 patients at clinical sites around the globe. Details on site locations and when recruitment will start…

Suppressing the production of a protein called NPAS2 eased signs of lung scarring (fibrosis) in a mouse model of idiopathic pulmonary fibrosis (IPF), a new study showed. The NPAS2 gene, which codes for NPAS2, also was found to be more active in the lungs of IPF patients than in those…

Treatment with mesenchymal stem cells (MSCs) bound to tiny vesicles loaded with Ofev’s active ingredient reduced lung inflammation and scarring while  promoting lung tissue repair in a mouse model of pulmonary fibrosis (PF), a study has shown. This combination strategy worked better than Ofev alone in both young…